Refractory healing after surgical therapy of osteonecrosis of the jaw: associated risk factors in aged patients

References

• Ito R, Kubota K, Inui A, et al. Oral-maxillofacial trauma of a geriatric population in a super-ageing country. Dent Traumatol. 2017;33(6):433–437. doi:10.1111/edt.1237128887864
   PubMed Web of Science ®Google Scholar
• Sato Y, Kitagawa N, Isobe A. Implant treatment in ultra-aged society. Jpn Dent Sci Rev. 2018;54(2):45–51. doi:10.1016/j.jdsr.2017.12.00229755614
   PubMed Web of Science ®Google Scholar
• Lee F-H, Shen P-C, Jou IM, Li C-Y, Hsieh J-L. A population-based 16-year study on the risk factors of surgical site infection in patients after bone grafting: a cross-sectional study in Taiwan. Medicine. 2015;94(47):e2034. doi:10.1097/MD.000000000000087426632703
   PubMed Web of Science ®Google Scholar
• Singh ML, Papas A. Oral implications of polypharmacy in the elderly. Dent Clin North Am. 2014;58(4):783–796. doi:10.1016/j.cden.2014.07.00425201542
   PubMedGoogle Scholar
• Hong SO, Lee CY, Jung J, Kim DY, Walter C, Kwon YD. A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians. Clin Oral Investig.
   Web of Science ®Google Scholar
• Baur DA, Altay MA, Flores-Hidalgo A, Ort Y, Quereshy FA. Chronic osteomyelitis of the mandible: diagnosis and management–an institution’s experience over 7 years. J Oral Maxillofac Surg. 2015;73(4):655–665. doi:10.1016/j.joms.2014.10.01725577460
   PubMed Web of Science ®Google Scholar
• Manzon L, Ettorre E, Viscogliosi G, et al. Bisphosphonate therapy and osteonecrosis of the jaw complicated with a temporal abscess in an elderly woman with rheumatoid arthritis: a case report. Clin Interv Aging. 2014;9:1409–1413. doi:10.2147/CIA.S6772625187700
   PubMed Web of Science ®Google Scholar
• Ramaglia L, Guida A, Iorio-Siciliano V, Cuozzo A, Blasi A, Sculean A. Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investig. 2018;22(2):597–615. doi:10.1007/s00784-017-2325-6
   PubMed Web of Science ®Google Scholar
• Guimaraes EP, Pedreira FR, Jham BC, de Carli ML, Pereira AA, Hanemann JA Clinical management of suppurative osteomyelitis, bisphosphonate-related osteonecrosis, and osteoradionecrosis: report of three cases and review of the literature. Case Rep Dent. 2013;2013:402096.24222866
   PubMedGoogle Scholar
• Alsehimy M, Al-Dharrab A. Risk factor assessment of osteomyelitis of the jaws in the Saudi population: a 10-year retrospective study. Egypt J Oral Maxillofac Surg. 2012;3(1):23–29. doi:10.1097/01.OMX.0000412879.34163.b4
   Google Scholar
• Kim HY, Lee SJ, Kim SM, et al. Extensive surgical procedures result in better treatment outcomes for bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis. J Oral Maxillofac Surg. 2017;75(7):1404–1413. doi:10.1016/j.joms.2016.12.01428039736
   PubMed Web of Science ®Google Scholar
• McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2018;24(4):527–536. doi:10.1111/odi.1270828656643
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–1956. doi:10.1016/j.joms.2014.04.03125234529
   PubMed Web of Science ®Google Scholar
• Pincus DJ, Armstrong MB, Thaller SR. Osteomyelitis of the craniofacial skeleton. Semin Plast Surg. 2009;23(2):73–79. doi:10.1055/s-0029-121415920567729
   PubMedGoogle Scholar
• Lopes RN, Rabelo GD, Rocha AC, Carvalho PA, Alves FA. Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: six-year experience of a single institution. J Oral Maxillofac Surg. 2015;73(7):1288–1295. doi:10.1016/j.joms.2015.01.00825871903
   PubMed Web of Science ®Google Scholar
• Mo L, Ding D, Pu S-Y, et al. Patients aged 80 years or older are encountered more potentially inappropriate medication use. Chin Med J. 2016;129(1):22–27. doi:10.4103/0366-6999.17255826712428
   PubMed Web of Science ®Google Scholar
• Busti AJ, Hooper JS, Amaya CJ, Kazi S. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy. 2012;25(11):1566–1591. doi:10.1592/phco.2005.25.11.1566
   Web of Science ®Google Scholar
• Jain A, Witbreuk M, Ball C, Nanchahal J. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg Am. 2002;27(3):449–455.12015719
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Yamori M, Tanaka S, et al. Risk factors and indices of osteomyelitis of the jaw in osteoporosis patients: results from a hospital-based cohort study in Japan. PLoS One. 2013;8(11):e79376–e79376. doi:10.1371/journal.pone.007937624223935
   PubMed Web of Science ®Google Scholar
• Molcho S, Peer A, Berg T, Futerman B, Khamaisi M. Diabetes microvascular disease and the risk for bisphosphonate-related osteonecrosis of the jaw: a single center study. J Clin Endocrinol Metab. 2013;98(11):E1807–1812. doi:10.1210/jc.2013-243424037883
   PubMed Web of Science ®Google Scholar
• Kajizono M, Sada H, Sugiura Y, et al. Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study. Biol Pharm Bull. 2015;38(12):1850–1855. doi:10.1248/bpb.b15-0038526632176
   PubMed Web of Science ®Google Scholar
• Paek SJ, Park WJ, Shin HS, Choi MG, Kwon KH, Choi EJ. Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg. 2016;42(5):271–277. doi:10.5125/jkaoms.2016.42.5.27127847735
   PubMedGoogle Scholar
• Yamazaki T, Yamori M, Yamamoto K, et al. Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: a hospital-based cohort study in Japan. Bone. 2012;51(5):882–887. doi:10.1016/j.bone.2012.08.11522917933
   PubMed Web of Science ®Google Scholar
• Isidro ML, Ruano B. Bone disease in diabetes. Curr Diabetes Rev. 2010;6(3):144–155.20380629
   PubMedGoogle Scholar
• Peer A, Khamaisi M. Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res. 2015;94(2):252–260. doi:10.1177/002203451456076825477311
   PubMed Web of Science ®Google Scholar
• Berti-Couto SA, Vasconcelos AC, Iglesias JE, Figueiredo MA, Salum FG, Cherubini K. Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats. Head Neck. 2014;36(1):84–93. doi:10.1002/hed.2326023649954
   PubMed Web of Science ®Google Scholar
• Favus MJ. Diabetes and the risk of osteonecrosis of the jaw. J Clin Endocrinol Metab. 2007;92(3):817–818. doi:10.1210/jc.2007-009817341579
   PubMed Web of Science ®Google Scholar
• Chiu CT, Chiang WF, Chuang CY, Chang SW. Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw–a serial case analysis. J Oral Maxillofac Surg. 2010;68(5):1055–1063. doi:10.1016/j.joms.2009.12.03020403529
   PubMed Web of Science ®Google Scholar
• Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis - an untreatable disease? Nat Rev Drug Discov. 2005;4(4):331–344. doi:10.1038/nrd169315803196
   PubMed Web of Science ®Google Scholar
• Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. doi:10.1186/1710-1492-9-3023947590
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102(2):274–282. doi:10.1172/JCI27999664068
   PubMed Web of Science ®Google Scholar
• Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341–1347. doi:10.1093/annonc/mdr43521986094
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–1491. doi:10.1359/jbmr.0707onj17663640
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Schwartz K, Rejnmark L, Mosekilde L, Pinholt EM. Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study. J Oral Maxillofac Surg. 2012;70(4):821–829. doi:10.1016/j.joms.2011.02.09321764202
   PubMed Web of Science ®Google Scholar